HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target
Authors
Keywords
-
Journal
Cell Death Discovery
Volume 9, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-28
DOI
10.1038/s41420-023-01692-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors
- (2021) Emily Capone et al. Pharmaceutics
- Anti‑HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma
- (2021) Teizo Asano et al. ONCOLOGY REPORTS
- HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
- (2020) Lucía Gandullo‐Sánchez et al. EMBO Molecular Medicine
- U3-1402, a novel HER3-targeting antibody-drug conjugate, for the treatment of Colorectal Cancer
- (2019) Shigehiro Koganemaru et al. MOLECULAR CANCER THERAPEUTICS
- HER2-targeted therapies — a role beyond breast cancer
- (2019) Do-Youn Oh et al. Nature Reviews Clinical Oncology
- Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-LineRASWild-Type Metastatic Colorectal Cancer
- (2018) Andrew G. Hill et al. CLINICAL CANCER RESEARCH
- EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma
- (2018) Emily Capone et al. JOURNAL OF CONTROLLED RELEASE
- Understanding the biology of HER3 receptor as a therapeutic target in human cancer
- (2018) Hui Lyu et al. Acta Pharmaceutica Sinica B
- EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma
- (2017) Emily Capone et al. Oncotarget
- HER3 expression is correlated to distally located and low-grade colon cancer
- (2016) Frida Lédel et al. ACTA ONCOLOGICA
- A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan
- (2016) James M. Cleary et al. INVESTIGATIONAL NEW DRUGS
- Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus
- (2015) René Adam et al. CANCER TREATMENT REVIEWS
- Prognostic relevance of LGALS3BP in human colorectal carcinoma
- (2015) Enza Piccolo et al. Journal of Translational Medicine
- HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer
- (2015) Hanna Styczen et al. Oncotarget
- ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
- (2014) Carlos L. Arteaga et al. CANCER CELL
- EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo
- (2014) Gianluca Sala et al. Translational Oncology
- Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer
- (2014) R Ghasemi et al. Oncogenesis
- The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer
- (2013) Ching-Wen Huang et al. BMC CANCER
- Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
- (2013) P. LoRusso et al. CLINICAL CANCER RESEARCH
- HER3 expression in patients with primary colorectal cancer and corresponding lymph node metastases related to clinical outcome
- (2013) F. Lédel et al. EUROPEAN JOURNAL OF CANCER
- Metastatic recurrence after complete resection of colorectal liver metastases: impact of surgery and chemotherapy on survival
- (2013) K. Homayounfar et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- A view on EGFR-targeted therapies from the oncogene-addiction perspective
- (2013) Rolando Perez et al. Frontiers in Pharmacology
- Toward the Prognostic Significance and Therapeutic Potential of HER3 Receptor Tyrosine Kinase in Human Colon Cancer
- (2011) A. Beji et al. CLINICAL CANCER RESEARCH
- An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling
- (2011) G Sala et al. ONCOGENE
- Standardized surgery for colonic cancer: complete mesocolic excision and central ligation - technical notes and outcome
- (2008) W. Hohenberger et al. Colorectal Disease
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now